Use of antibody as carrier of oligomers of peptidomimetic αvβ3 antagonist to target tumor-induced neovasculature

Bioconjugate Chemistry

Volumn 18, Issue 3, 2007, Pages 821-828

  In, Soo Shin ^a   Jang, Beom Su ^a   Danthi, S Narasimhan ^a   Xie, Jianwu ^a   Yu, Sarah ^a   Le, Nhat ^a   Maeng, Jin Soo ^a   In, Sook Hwang ^a   Li, King C P ^a,c   Carrasquillo, Jorge A ^a,b   Paik, Chang H ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLATION; AMINO ACIDS; CROSSLINKING; OLIGOMERS; POLYETHYLENE GLYCOLS; TUMORS;

DEACETYLATION; INTEGRINS; NEOVASCULATURE; PEPTIDOMIMETICS; RECEPTOR BINDING; SELECTIVE REACTIONS; SULFHYDRYL; SULFHYDRYL GROUPS; TUMOR UPTAKE; Β-ALANINE;

MONOCLONAL ANTIBODIES;

1,8 BIS(MALEIMIDO)DIETHYLENE GLYCOL; 4 [2 (3,4,5,6 TETRAHYDROPYRIMIDINE 2 YLAMINO)ETHYLOXY]BENZOYL 2 AMINOETHYLSULFONYLAMINO BETA ALANINE; ACETYLTHIOACETATE DERIVATIVE; EDETIC ACID; ETHYLENE GLYCOL; HYDROXYLAMINE; IODINE 125; LECTIN; MONOCLONAL ANTIBODY; RHODAMINE; SUCCINIMIDE DERIVATIVE; THIOL DERIVATIVE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VTIRONECTIN RECEPTOR ANTAGONIST;

ANTIBODY DETECTION; ARTICLE; DEACETYLATION; EX VIVO STUDY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MACROMOLECULE; MOLECULAR INTERACTION; MOLECULAR WEIGHT; NEOVASCULARIZATION (PATHOLOGY); OLIGOMERIZATION; PH MEASUREMENT; PROTEIN CROSS LINKING; RADIOACTIVITY; REACTION OPTIMIZATION; RECEPTOR BINDING;

MUS MUSCULUS;

EID: 34347355551     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0603485     Document Type: Article

References (45)

1. Risau, W. (1995) Differentiation of endothelium. FASEB J. 9, 926-933.
2. Takagi, J., and Springer, T. A. (2002) Integrin activation and structural rearrangement. Immunol. Rev. 186, 141-163.
3. Clezardin, P. (1998) Recent insights into the role of integrins in cancer metastasis. Cell. Mol. Life Sci. 54, 541-548.
4. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31.
5. Stromblad, S., and Cheresh, D. A. (1996) Integrins, angiogenesis and vascular cell survival. Chem. Biol. 3, 881-885.
6. Ruoslahti, E., and Pierschbacher, M. D. (1986) Arg-Gly-Asp: a versatile cell recognition signal. Cell 44, 517-518.
7. v3 integrin antagonists: a new class of tracers for tumor targeting. J. Nucl. Med. 40, 1061-1071.
8. van Hagen, P. M., Breeman, W. A., Bernard, H. F., Schaar, M., Mooij, C. M., Srinivasan, A., Schmidt, M. A., Krenning, E. P., and de Jong, M. (2000) Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int. J. Cancer 90, 186-198.
9. 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother. Radiopharm. 18, 627-641.
10. v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjugate Chem. 15, 41-49.
11. 3 expression. Nuklearmedizin 43, 26-32.
12. 3-targeted imaging of lung cancer. Neoplasia 7, 271-279.
13. Naimushin, Y. A., and Mazurov, A. V. (2005) Ability of different glycoprotein IIb-IIIa ligands to support platelet aggregation induced by activating antibody CRC54. Biochemistry (Moscow, Russ. Fed.) 70, 782-789.
14. DeNardo, S. J., Burke, P. A., Leigh, B. R., O'Donnell, R. T., Miers, L. A., Kroger, L. A., Goodman, S. L., Matzku, S., Jonczyk, A., Lamborn, K. R., and DeNardo, G. L. (2000) Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother. Radiopharm. 15, 71-79.
15. Burke, P. A., DeNardo, S. J., Miers, L. A., Kukis, D. L., and DeNardo, G. L. (2002) Combined modality radioimmunotherapy. Promise and peril. Cancer 94, 1320-1331.
16. Bernard, B., Capello, A., van Hagen, M., Breeman, W., Srinivasan, A., Schmidt, M., Erion, J., van Gameren, A., Krenning, E., and de Jong, M. (2004) Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy. Cancer Biother. Radiopharm. 19, 173-180.
17. Capello, A., Krenning, E. P., Bernard, B. F., Breeman, W. A., van Hagen, M. P., and de Jong, M. (2004) Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J. Nucl. Med. 45, 1716-1720.
18. 3-integrin expression. J. Nucl. Med. 45, 1776-1783.
19. v- integrin expression with 64Cu-labeled dimeric RGD peptides. Mol. Imaging Biol. 6, 350-359.
20. Li, L., Wartchow, C. A., Danthi, S. N., Shen, Z., Dechene, N., Pease, J., Choi, H. S., Doede, T., Chu, P., Ning, S., Lee, D. Y., Bednarski, M. D., and Knox, S. J. (2004) A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int. J. Radiat. Oncol. Biol. Phys. 58, 1215-1227.
21. Janssen, M., Frielink, C., Dijkgraaf, I., Oyen, W., Edwards, D. S., Liu, S., Rajopadhye, M., Massuger, L., Corstens, F., and Boerman, O. (2004) Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother. Radiopharm. 19, 399-404.
22. 3 receptor antagonist: different but biologically equivalent. Bioconjugate Chem. 15, 235-241.
23. 3 expression using (64)Cu-labeled tetrameric RGD peptide. J. Nucl. Med. 46, 1707-1718.
24. Capello, A., Krenning, E. P., Bernard, B. F., Breeman, W. A., Erion, J. L., and de Jong, M. (2006) Anticancer activity of targeted proapoptotic peptides. J. Nucl. Med. 47, 122-129.
25. Haubner, R., Wester, H. J., Burkhart, F., Senekowitsch-Schmidtke, R., Weber, W., Goodman, S. L., Kessler, H., and Schwaiger, M. (2001) Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42, 326-336.
26. Li, J., Ji, J., Holmes, L. M., Burgin, K. E., Barton, L. B., Yu, X., Wagner, T. E., and Wei, Y. (2004) Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor. Cancer Gene Ther. 11, 363-370.
27. 3 integrin directed therapeutics. Bioconjugate Chem. 13, 128-135.
28. 3-expressing endothelial cells. Int. J. Cancer 112, 279-285.
29. 3-targeted molecular probe for optical imaging of tumor. Bioorg. Med. Chem. 13, 3763-3771.
30. Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., and Cheresh, D. A. (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404-2407.
31. Reardan, D. T., Meares, C. F., Goodwin, D. A., McTigue, M., David, G. S., Stone, M. R., Leung, J. P., Bartholomew, R. M., and Frincke, J. M. (1985) Antibodies against metal chelates. Nature (London) 316, 265-268.
32. Goodwin, D. A., Meares, C. F., McCall, M. J., McTigue, M., and Chaovapong, W. (1988) Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J. Nucl. Med. 29, 226-234.
33. Barbet, J., Peltier, P., Bardet, S., Vuillez, J. P., Bachelot, I., Denet, S., Olivier, P., Leccia, F., Corcuff, B., Huglo, D., Proye, C., Rouvier, E., Meyer, P., and Chatal, J. F. (1998) Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J. Nucl. Med. 39, 1172-1178.
34. Corneillie, T. M., Whetstone, P. A., Lee, K. C., Wong, J. P., and Meares, C. F. (2004) Converting weak binders into infinite binders. Bioconjugate Chem. 15, 1389-1391.
35. Corneillie, T. M., Lee, K. C., Whetstone, P. A., Wong, J. P., and Meares, C. F. (2004) Irreversible engineering of the multielement-binding antibody 2D12.5 and its complementary ligands. Bioconjugate Chem. 15, 1392-1402.
36. Sharkey, R. M., Cardillo, T. M., Rossi, E. A., Chang, C. H., Karacay, H., McBride, W. J., Hansen, H. J., Horak, I. D., and Goldenberg, D. M. (2005) Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat. Med. 11, 1250-1255.
37. Hnatowich, D. J., Virzi, F., and Rusckowski, M. (1987) Investigations of avidin and biotin for imaging applications. J. Nucl. Med. 28, 1294-1302.
38. Paganelli, G., Magnani, P., Zito, F., Villa, E., Sudati, F., Lopalco, L., Rossetti, C., Malcovati, M., Chiolerio, F., and Seccamani, E. (1991) Three-step monoclonal antibody tumor targeting in carcino-embryonic antigen-positive patients. Cancer Res. 51, 5960-5966.
39. 90Y radioimmunotherapy in a mouse xenograft model. J. Immunother. 16, 158.
40. Cremonesi, M., Ferrari, M., Chinol, M., Stabin, M. G., Grana, C., Prisco, G., Robertson, C., Tosi, G., and Paganelli, G. (1999) Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients. Eur. J. Nucl. Med. 26, 110-120.
41. Sato, N., Hassan, R., Axworthy, D. B., Wong, K. J., Yu, S., Theodore, L. J., Lin, Y., Park, L., Brechbiel, M. W., Pastan, I., Paik, C. H., and Carrasquillo, J. A. (2005) Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J. Nucl. Med. 46, 1201-1209.
42. Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J., and Chatal, J. F. (2006) Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 24, 823-834.
43. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
44. Kinuya, S., Jeong, J. M., Garmestani, K., Saga, T., Camera, L., Brechbiel, M. W., Gansow, O. A., Carrasquillo, J. A., Neumann, R. D., and Paik, C. H. (1994) Effect of metabolism on retention of indium-111-labeled monoclonal antibody in liver and blood. J. Nucl. Med. 35, 1851-1857.
45. Camera, L., Kinuya, S., Garmestani, K., Wu, C., Brechbiel, M. W., Pai, L. H., McMurry, T. J., Gansow, O. A., Pastan, I., Paik, C. H., Carrasquillo, J. A. (1994) Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J. Nucl. Med. 35, 882-889.